Biotricity Inc. (BTCY) intrinsic value & 10-year financials
Biotricity Inc. (BTCY) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 69.5% a year to $16.0M, with an average return on invested capital of 277.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.05
- Market cap
- $1.4M
- Revenue (FY2026)
- $16.0M
- Revenue growth (10-yr CAGR)
- 69.5%
- ROIC (10-yr avg)
- 277.0%
- Free cash flow (FY2026)
- —
BTCY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | $16.0M | -$2.4M | -$0.12 | — | 10.6% | 7.5% |
| FY2025 | $13.8M | -$8.4M | -$0.56 | — | -17.8% | 26.6% |
| FY2024 | $12.1M | -$14.1M | -$1.66 | — | -73.2% | 56.0% |
| FY2023 | $9.6M | -$18.7M | -$2.26 | — | -159.9% | 116.2% |
| FY2022 | $7.7M | -$29.1M | — | -$15.2M | -218.8% | 222.5% |
| FY2021 | $3.4M | -$15.5M | — | — | — | 397.9% |
| FY2020 | $1.4M | -$11.1M | — | — | — | 284.3% |
| FY2019 | $398.2K | -$8.6M | — | — | — | 1071.0% |
| FY2018 | — | -$8.6M | — | — | — | 409.5% |
| FY2017 | — | -$7.8M | — | — | — | 178.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOTRICITY INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BIOTRICITY INC. has earned high returns on invested capital, averaging 23.2% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
BIOTRICITY INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOTRICITY INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-3.82 per share.